294 related articles for article (PubMed ID: 26169690)
1. DNA methylation of oestrogen-regulated enhancers defines endocrine sensitivity in breast cancer.
Stone A; Zotenko E; Locke WJ; Korbie D; Millar EK; Pidsley R; Stirzaker C; Graham P; Trau M; Musgrove EA; Nicholson RI; Gee JM; Clark SJ
Nat Commun; 2015 Jul; 6():7758. PubMed ID: 26169690
[TBL] [Abstract][Full Text] [Related]
2. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).
Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W
Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563
[TBL] [Abstract][Full Text] [Related]
3. Transcriptional implications of intragenic DNA methylation in the oestrogen receptor alpha gene in breast cancer cells and tissues.
Shenker NS; Flower KJ; Wilhelm-Benartzi CS; Dai W; Bell E; Gore E; El Bahrawy M; Weaver G; Brown R; Flanagan JM
BMC Cancer; 2015 May; 15():337. PubMed ID: 25927974
[TBL] [Abstract][Full Text] [Related]
4. Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer.
Sokol ES; Feng YX; Jin DX; Basudan A; Lee AV; Atkinson JM; Chen J; Stephens PJ; Frampton GM; Gupta PB; Ross JS; Chung JH; Oesterreich S; Ali SM; Hartmaier RJ
Ann Oncol; 2019 Jan; 30(1):115-123. PubMed ID: 30423024
[TBL] [Abstract][Full Text] [Related]
5. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
[TBL] [Abstract][Full Text] [Related]
6. Enhanced resistance to tamoxifen by the c-ABL proto-oncogene in breast cancer.
Zhao H; Ou-Yang F; Chen IF; Hou MF; Yuan SS; Chang HL; Lee YC; Plattner R; Waltz SE; Ho SM; Sims J; Wang SC
Neoplasia; 2010 Mar; 12(3):214-23. PubMed ID: 20234815
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.
Wardell SE; Ellis MJ; Alley HM; Eisele K; VanArsdale T; Dann SG; Arndt KT; Primeau T; Griffin E; Shao J; Crowder R; Lai JP; Norris JD; McDonnell DP; Li S
Clin Cancer Res; 2015 Nov; 21(22):5121-5130. PubMed ID: 25991817
[TBL] [Abstract][Full Text] [Related]
8. The promoter C specific ERalpha isoform is associated with tamoxifen outcome in breast cancer.
Amaral S; Schroth W; Kugler S; Fritz P; Simon W; Brauch H
Breast Cancer Res Treat; 2009 Nov; 118(2):323-31. PubMed ID: 19011961
[TBL] [Abstract][Full Text] [Related]
9. ESR1 and PGR gene promoter methylation and correlations with estrogen and progesterone receptors in ductal and lobular breast cancer.
Medina-Jaime AD; Reyes-Vargas F; Martinez-Gaytan V; Zambrano-Galvan G; Portillo-Delcampo E; Burciaga-Nava JA; Reyes-Romero M; Sifuentes-Alvarez A
Asian Pac J Cancer Prev; 2014; 15(7):3041-4. PubMed ID: 24815444
[TBL] [Abstract][Full Text] [Related]
10. Transcriptional coregualtor NUPR1 maintains tamoxifen resistance in breast cancer cells.
Wang L; Sun J; Yin Y; Sun Y; Ma J; Zhou R; Chang X; Li D; Yao Z; Tian S; Zhang K; Liu Z; Ma Z
Cell Death Dis; 2021 Feb; 12(2):149. PubMed ID: 33542201
[TBL] [Abstract][Full Text] [Related]
11. Tamoxifen-resistant breast cancers show less frequent methylation of the estrogen receptor beta but not the estrogen receptor alpha gene.
Chang HG; Kim SJ; Chung KW; Noh DY; Kwon Y; Lee ES; Kang HS
J Mol Med (Berl); 2005 Feb; 83(2):132-9. PubMed ID: 15536519
[TBL] [Abstract][Full Text] [Related]
12. ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer.
Jeselsohn R; Buchwalter G; De Angelis C; Brown M; Schiff R
Nat Rev Clin Oncol; 2015 Oct; 12(10):573-83. PubMed ID: 26122181
[TBL] [Abstract][Full Text] [Related]
13. D538G mutation in estrogen receptor-α: A novel mechanism for acquired endocrine resistance in breast cancer.
Merenbakh-Lamin K; Ben-Baruch N; Yeheskel A; Dvir A; Soussan-Gutman L; Jeselsohn R; Yelensky R; Brown M; Miller VA; Sarid D; Rizel S; Klein B; Rubinek T; Wolf I
Cancer Res; 2013 Dec; 73(23):6856-64. PubMed ID: 24217577
[TBL] [Abstract][Full Text] [Related]
14. Histone methyltransferases regulate the transcriptional expression of ERα and the proliferation of tamoxifen-resistant breast cancer cells.
Kim SS; Lee MH; Lee MO
Breast Cancer Res Treat; 2020 Feb; 180(1):45-54. PubMed ID: 31897900
[TBL] [Abstract][Full Text] [Related]
15. Amplification of ESR1 may predict resistance to adjuvant tamoxifen in postmenopausal patients with hormone receptor positive breast cancer.
Nielsen KV; Ejlertsen B; Müller S; Møller S; Rasmussen BB; Balslev E; Lænkholm AV; Christiansen P; Mouridsen HT
Breast Cancer Res Treat; 2011 Jun; 127(2):345-55. PubMed ID: 20556506
[TBL] [Abstract][Full Text] [Related]
16. Estrogen receptor mutations and their role in breast cancer progression.
Alluri PG; Speers C; Chinnaiyan AM
Breast Cancer Res; 2014 Dec; 16(6):494. PubMed ID: 25928204
[TBL] [Abstract][Full Text] [Related]
17. Hormone receptor-positive invasive lobular and ductal carcinoma of the breast have comparable hormone receptor expression levels both if detected by screening and clinically.
Ravaioli A; Falcini F; Bucchi L
Breast Cancer Res Treat; 2018 Feb; 167(3):817-818. PubMed ID: 29027616
[No Abstract] [Full Text] [Related]
18. The Role of ESR1 Gene Polymorphic Markers in the Development of Breast Cancer and Resistance to Tamoxifen Therapy.
Lukina SS; Burdennyy AM; Zavarykina TM; Riabchikov DA; Kazubskaya TP; Kruglova MP; Loginov VI
Bull Exp Biol Med; 2021 Jan; 170(3):350-355. PubMed ID: 33452979
[TBL] [Abstract][Full Text] [Related]
19. The prognostic value of MEK pathway-associated estrogen receptor signaling activity for female cancers.
Ng CW; Tsang YTM; Gershenson DM; Wong KK
Br J Cancer; 2024 May; 130(11):1875-1884. PubMed ID: 38582811
[TBL] [Abstract][Full Text] [Related]
20. Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer.
Hartmaier RJ; Trabucco SE; Priedigkeit N; Chung JH; Parachoniak CA; Vanden Borre P; Morley S; Rosenzweig M; Gay LM; Goldberg ME; Suh J; Ali SM; Ross J; Leyland-Jones B; Young B; Williams C; Park B; Tsai M; Haley B; Peguero J; Callahan RD; Sachelarie I; Cho J; Atkinson JM; Bahreini A; Nagle AM; Puhalla SL; Watters RJ; Erdogan-Yildirim Z; Cao L; Oesterreich S; Mathew A; Lucas PC; Davidson NE; Brufsky AM; Frampton GM; Stephens PJ; Chmielecki J; Lee AV
Ann Oncol; 2018 Apr; 29(4):872-880. PubMed ID: 29360925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
